Page 4 - David Berd News Today

Share this article FN Media Group Presents USA News Group News Commentary VANCOUVER, BC, March 12, 2021 /PRNewswire/ -- USA News Group  -  Rollouts of two approved COVID-19 vaccines have for the past few months started making their way into markets around the world. Amid the attention given to COVID vaccines, new vaccines that target different types of cancers are gaining momentum. In the UK, enthusiasm has been growing for a four-year-old girl attempting to raise £100,000 in less than fou...

BVX-0320 and Covid-T to have capability to address UK, Brazilian and South African Virus Variants VANCOUVER, B.C., March 1, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:

Share this article Share this article USD$900,000 In-Kind Investment by Procare Health into Phase I Clinical Study for BVX-0918A in the EU Co-Development of Vaccines for Cervical Cancer and HPV Right of First Refusal for US Marketing of Papilocare™ VANCOUVER, BC and BARCELONA, Spain, Feb. 10, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF)  ("BioVaxys"), the world leader in haptenized protein vaccines for antiviral and cancer applications, and Procare Hea...

Glenmede Investment Management Celebrates 5th Anniversary for Women in Leadership U.S. Equity Strategy Glenmede Investment Management Celebrates 5th Anniversary for Women in Leadership U.S. Equity Strategy Glenmede Investment Management LP (GIM), a privately owned, independent asset management firm, recently celebrated the five-year anniversary of its Glenmede Women in Leadership US Equity Strategy (Strategy). With more than $25.6 million in assets under management as of September 30, 2020, th...

Close (Photo : BioVaxys: "Back to the Future" ) BioVaxys, a clinical-stage biopharma group, are excelling in the development of antiviral and anticancer immunotherapeutics. Their speciality? A haptenized antigen vaccine platform. Haptenization stimulates a robust immune response, as it "teaches" the patients immune system to recognise the target viral or tumor antigens as foreign. But how does it achieve this? The process of haptenization involves the modification of tumor cells, its viral pro...

Share this article Share this article PALM BEACH, Fla., Jan. 25, 2021 /PRNewswire/ -- Ovarian cancer is one of the most deadly gynecologic malignancy across the globe, but new treatments are gaining increased efficacy while displaying reduced toxicity. Clinical trials abound. Immunotherapy using immune-checkpoint modulators has been revolutionizing the oncology field far beyond their remarkable clinical efficacy in some patients. It creates radical changes in the evaluation of treatment efficac...

Features Observation Of Neutralizing Antibodies To SARS-CoV-2 Advancement Of Viral Vaccine Platform And T-cell Diagnostic To Address Emerging SARS-CoV-2 Strains BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys" or "Company") is pleased to provide a corporate update on recent advancements of its vaccine platforms, and viral diagnostic and corporate objectives for 2021. BioVaxys is pleased to announce that it has commenced the clinical development program for BVX-0918A, i...

Vancouver, BC –  January 25, 2021 – BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) (“BioVaxys” or “Company”) is pleased to provide a corporate update on recent advancements of its vaccine platforms, viral diagnostic and corporate objectives for 2021. BioVaxys is pleased to announce that it has commenced the clinical development program for BVX-0918A, its haptenized tumor antigen vaccine for ovarian cancer. The Company plans to seek a compassionate use approval in th...

  Vancouver, BC –  December 21, 2020 —  BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTC:LMNGF) (“BioVaxys”) announced today that further analysis of the data from a preclinical animal study (also known as the “murine model study”) of its haptenized viral protein vaccine technology show that BVX-0320, its Covid-19 vaccine candidate based on the Company’s haptenized viral protein platform, elicits a robust T-cell response against SARS-CoV-2.   Using a technique called flow c...

Share this article VANCOUVER, British Columbia, Dec. 21, 2020 /CNW/ -- BioVaxys Technology Corp. ( CSE: BIOV, FRA:5LB, OTC:LMNGF) ("BioVaxys") announced today that further analysis of the data from a preclinical animal study (also known as the "murine model study") of its haptenized viral protein vaccine technology show that BVX-0320, its COVID-19 vaccine candidate based on the Companys haptenized viral protein platform, elicits a robust T-cell response against SARS-CoV-2. Using a technique cal...